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Complement activation retards resolution of acute ischemic
renal failure in the rat
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Complement activation retards resolution of acute ischemic renal
failure in the rat. We investigated the role of complement activation on
the resolution of acute ischemic renal failure in the rat. Acute renal
failure was induced by clamping of the renal arteries of Sprague-Dawley
rats for 45 minutes (Day 0). On subsequent days, groups of rats with
acute renal failure were exposed to daily zymosan infusion (an activator
of the complement system), or to blood incubated with cuprophane
(CUP) or polyacrylonitrile (PAN) dialysis membranes. We serially
measured the change in BUN daily, glomerular filtration rate and
24-hour proteinuria on Day 3 and Day 5 following ischemia. On Day 6,
the animals were sacrificed and their kidneys examined histologically.
Zymosan and cuprophane exposed rats had a significant delay in the
recovery of renal failure, reduced glomerular filtration rate, and histo-
logically had more neutrophil infiltration than control or PAN exposed
animals. To investigate the potential pathophysiology of these obser-
vations, we assessed the response of zymosan-exposed rats to infusion
of deferoxamine (DFO), a potent inhibitor of hydroxyl radical formation
(0H). Infusion of DFO prior to zymosan significantly improved
recovery of renal function. We also measured urinary thromboxane B2
levels in these groups of rats. While the groups of rats exposed to
zymosan had the highest levels of thromboxane B2, these levels were
not different between the groups exposed to zymosan alone, or to
zymosan and DFO. These observations suggest a role for hydroxyl
radicals in the prolongation of renal failure in this model. Taken
together, these findings may have implications for the dialytic interven-
tion in patients with acute renal failure.
A number of reports have suggested that treatment of acute
renal failure by hemodialysis may prolong the course of renal
failure [1, 2] and may be associated with histological evidence
of focal areas of fresh tubular necrosis [3]. Although loss of
autoregulation of renal blood flow and episodes of hypotension
during hemodialysis have been suggested as the etiology of
these fresh ischemic lesions [1, 4—8], we investigated the
possibility that the type of dialysis membrane may also play a
role in the prolongation of acute renal failure.
During hemodialysis with cuprophane membranes, intense
activation of the complement system occurs via the alternative
pathway, resulting in transient systemic granulocytopenia
[9—li]. Pulmonary sequestration of neutrophils has been sug-
gested as the cause of this systemic granulocytopenia, based on
studies of 32P-labelled neutrophils in dogs exposed to the
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cuprophane membrane [12]. However, other studies suggest
that neutrophils may be sequestered in vascular beds of other
organs as well [13, 14].
Recent studies have highlighted the pathogenic role that
infiltrating leukocytes may play in selected models of renal
injuries. Systemic leukocyte depletion has been shown to
improve glomerular filtration rate (GFR) in the post-obstructive
renal injury model [15]. Pretreatment of animals with inhibitors
of leukotriene D4, a product of neutrophil activation, was
shown to improve resolution of the immunological injury in a
rat model [16]. Other studies have shown that the products of
neutrophil activation, such as neutrophil elastase and reactive
oxygen products, participated in renal injury [17, 18].
We therefore investigated the potential roles that comple-
ment and leukocyte activation, as well as the role of reactive
oxygen species (ROS), may play in the resolution of acute
ischemic renal failure in the rat. Our results indicate that
chronic exposure to either zymosan or the cuprophane dialysis
membrane, both well-known activators of the complement
system, is associated histologically with increased neutrophil
infiltration in the renal parenchyma, and functionally with delay
in the resolution of the acute renal failure. On the other hand,
rats exposed to a non-complement activating polyacrylonitrile
(PAN) membrane [19] or those receiving deferoxamine, an
inhibitor of hydroxyl ion formation [20] prior to zymosan
infusion did not differ from control animals with respect to
recovery from acute renal failure.
Methods
Animals
All experiments were performed on male Sprague-Dawley
rats weighing 200 to 230 grams (Harlan Sprague-Dawley, Indi-
ana, USA). Renal ischemia was induced by bilateral clamping
of renal arteries, as described below. The animals were anes-
thetized with ketamine hydrochloride (Park Davis, Morris
Plains, New Jersey, USA) at a dose of 100 mg/bOg body weight
intraperitoneally (i.p.), after placing the animal on a heated
animal board to maintain core temperature at 37°C. Indwelling
catheters with an I.D. of 0.025 inches (Braintree Scientific,
Braintree, Massachusetts, USA) were surgically secured in the
jugular vein and left femoral artery. The vascular catheters
were threaded under the skin and exteriorized at the back of the
neck. A steel cannula, enclosed in silastic tubing, was im-
planted in the bladder via a suprapubic incision and exteriorized
through the abdominal wall. The bladder was flushed with
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Time WBC
0 100%
5 mm 56%
10 mm 45%
20 mm 125%
30 mm 123%
normal saline and the cannula plugged with a stainless steel pin
so that the animal could void normally through the urethra,
reducing the likelihood of bladder infection. Both renal arteries
were identified via a midline abdominal incision. Three minutes
after the administration of heparin (500 U/kg i.v.), a vascular
clamp was placed across each of the renal arteries. At the end
of 45 minutes of ischemia, the clamps were removed. This was
considered Day 0.
Six groups of rats, with six rats in each group, were prepared
as described above. A control group of rats (Group Ctrl) was
monitored without subjecting them to additional procedures,
beyond the renal ischemia. A second group of rats with renal
failure was exposed daily to blood which had been incubated
with cuprophane dialysis membranes (Group CUP), and a third
group was exposed daily to blood incubated with PAN dialysis
membranes (Group PAN) as described below. A fourth group of
rats was injected daily with zymosan (Group ZYM). A fifth
group of rats was infused daily with deferoxamine (DFO) 30
minutes before injecting them with zymosan (Group
DFO+ZYM) and a sixth group of rats was sham-operated, with
no clamping of the renal arteries (Group SHAM). Starting one
day after surgery, experiments were carried out to assess renal
function.
Methods
Preparation of zymosan. Zymosan was prepared as a 1%
solution in PBS. After boiling in water for an hour, the solution
was spun at 2,000 g for 15 minutes and resuspended in 10 ml
PBS, to yield approximately io particles/mi. The solution was
then mixed with normal rat serum at a ratio of 1 to 3 (vol/vol)
and incubated at 37°C for one hour. Aliquots were then frozen
until use.
Zymosan treated rats. Zymosan treated animals (Group
ZYM) received 150 d/l00 gram body weight of this zymosan
activated serum, daily, on Days 1 to 7 via the jugular vein. The
zymosan was infused at least 60 minutes prior to the determi-
nation of GFR.
Another group of six rats was treated in identical fashion,
except that they were infused 30 minutes before zymosan
injection with a solution of deferroxamine (DFO) at a concen-
tration of 3.5 mg/100 d to provide a total DFO dose of 1,5
mg/l00 g body weight.
In preliminary experiments on six rats, aliquots of blood were
withdrawn at five minute intervals after injection of zymosan
and white blood cell count measured serially. White blood
counts decreased to approximately 45% of the initial value 10
minutes after injection and rebounded to approximately 125%,
20 minutes after zymosan injection (Table I). These changes in
WBC were not affected by prior treatment with DFO.
Dialyzer membrane exposed rats. Two other groups of rats
were separately exposed to cuprophane (Group CUP) or PAN
(Group PAN) hollow-fiber dialysis membranes. These mem-
branes were made into mini-dialyzers from the same fibers used
clinically; however, the number of fibers was approximately 250
to 300 fibers and the fiber bundle volume of these dialyzers was
approximately 1.5 ml.
Each day approximately 2 cc of blood was withdrawn in a
heparinized syringe from another (non-experimental) rat and
infused slowly in each of the previously sterilized mini-dialyzer.
The devices were then capped and incubated for 15 minutes at
37°C in a sterile incubator. The dialyzer was then connected to
the rat in each of the experimental groups (N = 6 for both
groups) via their jugular vein catheter and the blood infused
slowly by flushing with warmed normal saline over five minutes
into the rat, daily starting on Day 1. The infusion of blood
exposed to cuprophane membranes produced on average a 33
5% decrease in WBC, whereas infusion of blood in contact with
PAN membranes caused no notable change in white blood
count. Monitoring of tail blood pressure of the rats indicated no
major changes during the infusion (± 10 mm Hg of pre-infusion
systolic blood pressure).
Analytical methods. (1.) BUN. Fifty microliters of blood was
sampled daily in a microcentrifuge tube from each animal, spun
and serum BUN analyzed with a Beckman Analyzer II (Beck-
man mc, Fullerton, California, USA), using an enzymatic
conductivity rate method.
Serial daily changes in BUN in all experimental groups were
dependent on the peak BUN level achieved after bilateral acute
clamping of the renal arteries. Peak BUN levels were achieved
approximately 24 hours after the renal artery clamping and
varied from approximately 80 to 150 mg/dl. For this reason,
relative BUN changes defined as
Peak BUN — Daily BUN% resolution = x 100
Peak BUN — Baseline BUN
were calculated. This measurement adjusts for the variable
peak BUN levels achieved in different animals and reflects the
percent recovery from acute ischemic injury.
(2.) Clearance studies. On day 3 and Day 5 following bilateral
clamping of renal arteries, all rats were placed in a restraining
cage and the bladder pin was removed to allow collection of
urine [22]. The arterial line was connected to a pressure
transducer and blood pressure recorded throughout the study.
An i.v. infusion of inulin (3% inulin in normal saline) was given
at a rate of 12 d/l00 g body wt/min. After an equilibration time
of 60 minutes, exactly timed (20 to 30 minutes) urine collections
were made and the volume measured gravimetrically. Approx-
imately 100 to 140 d blood were collected in a microhematocrit
tube before and after each urine collection. After centrifugation
of blood samples, plasma and urine were analyzed for inulin
concentration. The plasma and urine concentrations of inulin
were measured, using a spectrophotometric assay [21] (Spec-
tronic 1201, Milton Roy) set at 620 nm.
(3.) Proteinuria. Twenty-four-hour urines were collected in
all five groups of rats immediately prior to the determination of
inulin clearance studies on Day 3 and Day 5. Urine was
analyzed for protein concentration by the Coomassie blue urine
Table 1. WBC versus baseline (%) following infusion of zymosan(N = 6)
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1 2 3 4 5
Time, days after clamping
Fig. 1. Fractional change in BUN of dtlferent groups of rats, exposed
to zymosan (A), cuprophane membrane (0), polyacrylonitrile (X) and
control (•). Statistical differences are as shown in Table 2.
protein assay [211, using a spectrophotometer (Spectronic 1201,
Milton-1oy) set at 595 nm. All assays were done in duplicate.
(4.) Histology. To define histological changes in renal paren-
chyma, rats from each of the experimental groups were sacri-
ficed for morphological studies of the kidneys 30 minutes after
the last exposure to zymosan, cuprophane or PAN membrane
using Nembutal, 500 mg/kg i.p. The kidneys were harvested,
cross sectioned and immediately placed in 10% buffered neutral
formalin and processed routinely. Sections (3 to 4 ithick) were
stained with periodic acid-Schiff (PAS) and examined under
high magnification. All glomeruli (50) in a single thin section
were examined. Polymorphonuclear (PMN) leukocytes were
easily detected by their characteristic multilobed nuclei and
PAS positivity.
We also assessed in a blinded fashion, the extent of PMN
infiltration in the cortex and vasa recta separately, by examin-
ing the number of PMN in 10 random, high power microscopic
fields in cortical peritubular capillaries (PMN/cortex) and in 10
random, high power fields of medulla for PMN infiltration of the
vasa recta (PMN/vasa recta).
The extent of tubular injury was assessed on a relative score
of 1 to 10 (10 being the worst) by examining in at least 10 high
power fields under 40x objective the extent of tubular atrophy,
vacuolization, blebbing, intratubular costs, and dilatation and
interstitial fibrosis. The results are expressed average injury
score per tubular profile. All tissue was examined without
knowledge of the treatment protocol.
Group Day 2 Day 3 Day 5 Day 6
CTRL
PAN
ZYM
CUP
66 7.4
86 1.4
32 3.6
41 5.6
78 3.7A 91 2.90
86 2.1 A 95 2.20
49 3.9 B 69 2.00
53 5.5 B 71 3.40
93 2.6A
95 2.2 A
69 2.0 B
72 6.5 B
Table 3. GFR (tl/min/l0O g body wt)
Group Day 3 Day 5
Sham
CTRL
PAN
ZYM
DFO + ZYM
CUP
902 44 A
459±82B
440 46 B
267±13C
546 46 B
246 17 C
952 60A
801±52A
975 63A
463±68C
776 48 B
332 21 C
(5.) Urinary thromboxane B2 levels. Urinarythromboxane B2
levels were measured in urine collected during the GFR deter-
mination on Day 6 using a commercially available RIA kit
(Amersham, Arlington Heights, Illinois, USA). Although urine
has a high proportion of 2,3 dinor thromboxane B2, the antibody
used has cross reactivity of 38.4% with the dinor form, and was
used to compare the concentration of both compounds in the
urine of the different groups of rats.
Statistics
Results are expressed as means SEM. Statistical differences
were analyzed using the General Linear Model (GLM) proce-
dure for balanced data set (ANOVA), and the Bonferroni t-tests
of differences between means for the determination of level of
significance at a power (a) of 0.05, using the SAS computer
program [23]. In this analysis, the means with the same letter
designation (A, B, C, . . ) are not statistically different from
each other, whereas means with different letters are statistically
significantly different, at a level of P 0.05.
Results
The percent fractional recovery to baseline BUN level is
shown in Figure 1 and Table 2. Whereas the control and
PAN-dialyzer treated groups regained more than 90% of their
baseline renal function six days following ischemic injury, both
the zymosan (Group ZYM) and cuprophane (Group CUP)
groups of animals had achieved only 70% of their baseline BUN
values by six days. Importantly, Figure 1 suggests that this level
may have stabilized at five days. Results of glomerular filtration
rate (GFR), measured by inulin clearance, and carried out on
Days 3 and 5 for six rats in each experimental group are shown
in Table 3. The glomerular filtration rate of the control group
(Group Ctrl) of animals with bilateral ischemia, was (459 82
d/min/l00g body wt) statistically different (P < 0.003)from the
animals exposed to zymosan (267 13 pilmin/100g body wt) as
well as those in the CUP group (246 17 .dImin/l00 g body wt,
P < 0.05). However, GFR of the control group was not different
from the GFR of the PAN membrane exposed animals or to
those exposed to both DFO and zymosan, (Zymosan+DFO
group). Differences between the two groups was more evident
when their GFR was compared on Day 5 following surgery.
Table 2. Percent of fractional change in BUN (N = 6 for each group)
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Table 4. Twenty-four hour proteinuria (mg124 hrs)
Group Day 3 Day 6
Sham
CTRL
PAN
ZYM
DFO +
CUP
ZYM
14.1 2.1
22.0 2.2
21.1 1.8
29.2 3.8
24.8 1.5
24.1 1.6
16.2 0.5
16.8 3.9
19.2 1.1
28.0 4.1
15.4 1.0
27.2 2.6
Table 5. Number of PMNs in rat kidneys
Group
PMN in
cortex
(peritubular
PMN's/glomeruli capillaries)
PMN in
vasa recta
Sham
CTRL
PAN
ZYM
CUP
A
A
C
B
— —
0,06 0.20 1.33 0.7
0.1 0.1 2.33 1.2
0.68 0.37 8.60 2.5
0.32 0.07 5.17 2.6
—
0.67 0.7
0.83 0.4
4.8 1.72
2.17 1.8
Thus, GFR for the zymosan and cuprophane groups was still
significantly lower (463 68 d/min/l00 g body wt and 332 21
.d/min/100 g body wt, respectively) than control rats (801 52
d/min/l00 g body wt), PAN rats (975 63 p.lIminIlOO g body
wt) or rats exposed to DFO and zymosan (776 48 d/min/l00
g body wt, P  0.01).
Importantly, the rate of increase in GFR between Day 3 and
Day 5 was also different for the groups. Thus, the difference
between the GFR on Day 3 and Day 5 of the Ctrl group was 308
57 d/min/lO0 g body wt and 510 30 s1/min/100 g body wt
for the PAN group, respectively) while differences in GFR for
the same time period for the zymosan group was 144 6
dImin/100 g body wt (P  0.01 compared to control and PAN
dialyzer group), and 84 pi/min/l00 g body wt for the cuprophane
group (P < 0.001 compared to control and PAN dialyzer group).
As shown in Table 4, proteinuria was higher at both time
points for the zymosan and cuprophane groups than for the
control or PAN group. However, these differences were not
statistically significant either on Day 3 or on Day 5.
Histology
In control and sham-operated rats, glomeruli were unremark-
able and had virtually no leukocytes (0.06 0.2 PMNS/
glomerulus; Table 5). PAN exposed animals also had few
PMN's per glomeruli (0.1 0.1 PMNs/glomerulus). In contrast,
zymosan and cuprophane-exposed rats had marked increase in
PMNS in glomeruli, with 0.68 0.37 and 0.32 0.07 PMNS/
glomerulus, respectively (P < 00005 zymosan vs. control; P <
0.005 cuprophane vs. control).
The infiltration of PMN in and around peritubular capillaries
and in the vasa recta are also shown in Table 5. In general,
groups of rats that had high PMN/glomeruli also had high PMN
in the cortical capillaries and vasa recta and vice-versa. In all
groups, the extent of tubular injury was very mild and was not
different between groups (mean score for all groups 0.51 0.2),
and consisted of mild vacuolization and loss of brush border
focally.
Table 6. Urinary thromboxane B2 production (pg/mm)
Sham 227 93 A
CTRL 218 91 A
PAN 328 A
ZYM 671 128 B
DFO + ZYM 814 282 B
Urinary thromboxane
One hundred microliter aliquots of urine collected during
GFR determination was analyzed for thromboxane B2 levels.
The results are shown in Table 6. While the group of rats
exposed to zymosan had higher urinary thromboxane levels
(671 128 pg/mm) than rats in the control (227 93 pg/mm) or
PAN (218 91 pg/mm) groups, (There was not sufficient
samples for the CUP group of rats), there were no statistically
significant differences between the urinary thromboxane B2
values of the ZYM and DFO+ZYM (814 282 pg/mm) groups.
Discussion
Complement activation in response to zymosan or cu-
prophane membrane is a systemic phenomenon. During clinical
hemodialysis with cuprophane membrane, the white blood cell
count decreases to approximately 20% of its pre-dialysis value
at a time when only a fraction of the blood volume has been
exposed to the dialysis membrane [111. In view of the high
blood flow and its extensive glomerular capillary, sequestration
of neutrophils in the kidney should not be surprising. In this
study, we noted a marked increase in neutrophil infiltration in
renal parenchyma in both the zymosan and cuprophane-mem-
brane treated groups of animals compared to control and PAN
membrane treated groups of animals.
In addition to transient systemic neutropenia, complement
activation is also associated with several indices of leukocyte
activation [24—26]. Products of activated neutrophils have been
implicated in injury to glomerular and tubular structures [15,
27—30]. Experimental models of renal diseases such as acute
glomerulonephritis and interstitial nephritis, as well as ureteral
obstruction are characterized by the presence of polymorpho-
nuclear and other inflammatory cell infiltrates in the renal
parenchyma 131—34]. Although there is controversy regarding
the cause and effect of these infiltrates, there is growing
evidence that a number of inflammatory products mediated by
PMN's are involved in the pathogenesis of renal dysfunction.
The specific pathophysiological process that results in re-
duced renal function and proteinuria in association with com-
plement activation and neutrophil infiltration has not been fully
investigated in this study. Recent studies have indicated that
tubular epithelial cells produce reactive oxygen species (ROS)
following exposure to opsonized zymosan, suggesting that the
anaphylatoxins C3a and C5a may directly lead to cellular injury
[35]. The terminal sequence of complement activation, C5b9
(the membrane attack complex) has also been implicated in the
development of proteinuria and in the immunological sequence
of glomerular injury [36, 37]. Other studies have shown that
products of neutrophil activation, such as elastase and ROS
[38—44] play an important role in lipopolysaccharide-induced
renal injury. The beneficial effects of DFO infusion on recovery
of renal function in rats exposed to zymosan, suggests a
potential role of ROS in the pathophysiology of this process.
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However, other investigators have identified thromboxane A2
[45], LTD4 [16], PGE2 [46] as well as other neutrophil-derived
mediators as vasoconstrictors. Our results on urinary throm-
boxane B2 measurement, which may reflect the activation of
other cellular elements such as platelets and glomerular macro-
phages, indicate that there is increased urinary thromboxane B2
appearance following zymosan exposure. This was not blocked
by the prior administration of DFO. Nevertheless, the admin-
istration of DFO appeared to improve recovery of renal func-
tion. This suggests that thromboxane A2 may not be a direct
mediator of the injury produced by complement activation seen
in our model.
These observations have potential clinical implications for
the dialytic treatment of acute renal failure in humans. Patients
with acute renal failure often have a reduction in their residual
renal function once they are initiated on hemodialysis [1, 2].
This has been attributed to loss of renal autoregulation and the
imposition of further ischemic injury by episodes of hypoten-
sion or the loss of osmotic drive which occurs during dialysis
[4—8]. Although these are likely mechanisms, loss of residual
renal function often occurs in the absence of documented
hypotension. This study suggests that complement activation
such as occurs during dialysis with cuprophane membrane, the
most commonly used membrane for the treatment of acute renal
failure, may be a factor in the delayed resolution of acute renal
failure.
This rapid loss of residual renal function is also apparent in
patients with chronic renal failure who are initiated on hemo-
dialysis. Recent studies have shown that hemodialysis patients
lose their residual renal function more rapidly than patients
initiated on peritoneal dialysis [47, 48]. Although these studies
did not specifically address the type of dialyzer membrane used
in hemodialysis, the majority of patients initiated on hemodial-
ysis are dialyzed with cuprophane membrane. The validity of
the relationship between the exposure to dialysis membrane
and the loss of residual renal function needs to be confirmed by
prospective clinical studies currently underway.
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